| WELL |
Report |
Normalized FFO/share (Q2 2026) |
BEAT |
pred ~$1.58 vs. cons $1.547 |
HIGH |
| WELL |
Report |
SHO Same-Store NOI Growth YoY (Q2 2026) |
BEAT |
pred ~21.5% vs. cons 20.7% |
MEDIUM |
| WELL |
Report |
SHO Occupancy Rate (Q2 2026) |
IN-LINE |
pred ~88.3% vs. cons 88.1% |
MEDIUM |
| WELL |
Guide |
FY 2026 Normalized FFO/share (FY 2026) |
BETTER |
guide ~$6.41 midpoint vs. cons $6.298 |
HIGH |
| WELL |
Guide |
FY 2026 SHO SS NOI Growth (FY 2026) |
LOWER |
guide ~20.0% midpoint vs. cons 21.1% |
MEDIUM |
| WELL |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| WELL |
Return |
5-day cumulative residual |
-1.0% (STABILIZE) |
STABILIZE — FFO raise absorbed over 5 days; SHO guide miss limits recovery but capital deployment story provides floor |
MEDIUM |